CIZ — Cizzle Biotechnology Holdings Share Price
Last trade - 00:00- £7.73m
- £7.34m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 94.26 | ||
| Price to Tang. Book | 94.26 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -2664.63% | ||
| Return on Equity | -272.62% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | £m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Cizzle Biotechnology Holdings PLC is a United Kingdom-based diagnostics developer of early cancer tests. The Company is focused on early detection of lung cancer via the development of an immunoassay test for the CIZ1B biomarker. CIZ1B is a variant of CIZ1, a naturally occurring cell nuclear protein involved in protecting deoxyribonucleic acid (DNA). Its CIZ1B biomarker detects lung cancer at its earliest and most treatable stage. It is designed as a simple blood test, which enables early diagnosis before symptoms appear-when treatment options can transform outcomes for patients and families.
Directors
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- March 1st, 2007
- Public Since
- May 23rd, 2007
- No. of Employees
- 67
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- London Stock Exchange
- Shares in Issue
- 396,391,773
- Address
- 6th Floor, 60 Gracechurch Street, LONDON, EC3V 0HR
- Web
- https://cizzlebiotechnology.com/
- Phone
- +44 2074690930
- Auditors
- PKF Littlejohn LLP
Latest News for CIZ
Upcoming Events for CIZ
Similar to CIZ
4Basebio
London Stock Exchange
Arecor Therapeutics
London Stock Exchange
Avacta
London Stock Exchange
Batm Advanced Communications
London Stock Exchange
Bioventix
London Stock Exchange
FAQ
As of Today at 19:58 UTC, shares in Cizzle Biotechnology Holdings are trading at 1.95p. This share price information is delayed by 15 minutes.
Shares in Cizzle Biotechnology Holdings last closed at 1.95p and the price had moved by +14.71% over the past 365 days. In terms of relative price strength the Cizzle Biotechnology Holdings share price has outperformed the FTSE All Share Index by +3.37% over the past year.
There is no consensus recommendation for this security.
Find out moreCizzle Biotechnology Holdings does not currently pay a dividend.
Cizzle Biotechnology Holdings does not currently pay a dividend.
Cizzle Biotechnology Holdings does not currently pay a dividend.
To buy shares in Cizzle Biotechnology Holdings you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of 1.95p, shares in Cizzle Biotechnology Holdings had a market capitalisation of £7.73m.
Here are the trading details for Cizzle Biotechnology Holdings:
- Country of listing: United Kingdom
- Exchange: LSE
- Ticker Symbol: CIZ
Based on an overall assessment of its quality, value and momentum Cizzle Biotechnology Holdings is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Cizzle Biotechnology Holdings. Over the past six months, its share price has outperformed the FTSE All Share Index by +13.79%.
As of the last closing price of 1.95p, shares in Cizzle Biotechnology Holdings were trading +18.35% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Cizzle Biotechnology Holdings PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at 1.95p.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Cizzle Biotechnology Holdings' management team is headed by:
- Allan Syms - NEC
- Nigel Lee - FID
- Dawn Coverley - NED
- John Treacy - NED